Quote | Options | News | Analyst Ratings

Medivation Inc (MDVN)
Quote as of 10:20 AM ET 07/29/2010 (NASDAQ GM)
Last: 9.35 Change: ($0.09) Percent Change: -0.95 Volume: 12,938
Medivation, Inc. is a biopharmaceutical company. The Company focuses on the development of small molecule drugs to treat serious diseases. The Company?s product candidates in clinical development are dimebon (latrepirdine), which is in Phase III development for the treatment of Alzheimer?s disease and Huntington disease, and MDV3100, which is in Phase III development for the treatment of castration-resistant prostate cancer. Its dimebon program is partnered with Pfizer Inc. (Pfizer) and its MDV3100 program is partnered with Astellas Pharma Inc. (Astellas).
Analyst Opinions
  Current 1 Mo. 3 Mo.
Strong Buy 1.00 1.00 1.00
Buy 0.00 0.00 0.00
Hold 2.00 6.00 6.00
Sell 0.00 0.00 0.00
Strong Sell 0.00 1.00 1.00
  Average Recommendation
Current 1.67
1 Mo. Ago 2.00
3 Mo. Ago 2.00

Recommendation Scale

Strong Sell: 3.0 Hold: 2.0 Strong Buy: 1.0
- Sponsored Advertisement -
OptionsBuddy.com's covered call data is provided for information purposes only and should not be used or construed as an indicator of future performance. The information is not a solicitation, an offer to buy or sell, or a recommendation for any security. OptionsBuddy.com does not guarantee the accuracy or completeness of the information, or the suitability or potential value of any particular investment. Request a prospectus before investing. The term 'play' refers to placing a trade order. Returns on Investment (ROI) are based upon the option bid and the stock last. OTM ROI's do not take into account commission costs or loss of profit from options being excersized.
Copyright © 2006-2010 BuddyBuilder Software. All rights reserved.